Imprimis Pharma (IMMY) Misses Q4 EPS by 27c

Imprimis Pharma (NASDAQ: IMMY) reported Q4 EPS of ($0.53), $0.27 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $3.5 million versus the consensus estimate of $3.52 million.

For earnings history and earnings-related data on Imprimis Pharma (IMMY) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Barclays Upgrades Schott Pharma AG (1SXP:GR) to Overweight